Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan.

Reverse transcription polymerase chain reaction (RT-PCR) single-strand conformation polymorphism analysis was used to detect topoisomerase I (top1) mutations in total RNA from 16 specimens that were excised during surgery from eight patients with non-small cell lung cancer (NSCLC) who had received preoperative chemotherapy consisting of irinotecan (CPT-11) and cisplatin. PCR single-strand conformation polymorphism and subsequent DNA sequencing analysis showed two nucleotide substitutions resulting in Trp736stop (TGG to TGA) and Gly737Ser (GGT to AGT) in one tumor specimen. The mutations were located near a site in top1 that was previously reported to harbor a mutation in the human lung cancer cell line PC7/CPT, which was selected for CPT resistance. These results demonstrate that mutations in top1 occur after chemotherapy with CPT-11 in NSCLC patients and suggest that development of resistance to CPT-11 in some patients may involve mutation of top1. However, the significance of top1 mutations to CPT resistance needs to be further investigated.

[1]  R. Hertzberg,et al.  Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. , 1990, Molecular pharmacology.

[2]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[3]  Y. Pommier,et al.  Eukaryotic DNA topoisomerases I. , 1995, Biochimica et biophysica acta.

[4]  Y. Pommier,et al.  Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. , 1995, Cancer research.

[5]  M. Fukuoka,et al.  Irinotecan in small-cell lung cancer--Japanese trials. , 2000, Oncology.

[6]  M. Fukuda,et al.  Gene Mutation Analysis and Quantitation of DNA Topoisomerase I in Previously Untreated Non‐small Cell Lung Carcinomas , 1997, Japanese journal of cancer research : Gann.

[7]  J. Wang,et al.  Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. , 1993, Cancer research.

[8]  Eric Patterson,et al.  Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites , 1991, Nucleic Acids Res..

[9]  L. Doyle,et al.  Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. , 2001, Biochemical and biophysical research communications.

[10]  K. Shimokata,et al.  Higher expression of topoisomerase II in lung cancers than normal lung tissues: different expression pattern from topoisomerase I. , 1993, Biochemical and biophysical research communications.

[11]  D. Kufe,et al.  Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. , 1994, The Journal of biological chemistry.

[12]  T. Tsuruo,et al.  Retroviral expression of a mutant (GLY‐533) human DNA topoisomerase I cDNA confers a dominant form of camptothecin resistance , 1999, International journal of cancer.

[13]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.

[14]  M. Zelen.  Keynote address on biostatistics and data retrieval. , 1973, Cancer chemotherapy reports. Part 3.

[15]  M. Fukuoka,et al.  Point mutations of the topoisomerase IIalpha gene in patients with small cell lung cancer treated with etoposide. , 1996, Cancer research.

[16]  T. Tsuruo,et al.  Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. , 1990, Cancer research.

[17]  Y. Fujiwara,et al.  No Alteration in DNA Topoisomerase I Gene Related to CPT‐11 Resistance in Human Lung Cancer , 1996, Japanese journal of cancer research : Gann.

[18]  N. Saijo,et al.  Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. , 1992, Biochemical and biophysical research communications.

[19]  Y. Pommier,et al.  Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. , 2001, Cancer research.